Quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR study

被引：0

作者：

Karthaus, M. ^{[1
]}

Kretzschmar, A. ^{[2
]}

Welslau, M. ^{[3
]}

Riera-Knorrenschild, J. ^{[4
]}

Kaiser, F. ^{[5
]}

Pelz, H. ^{[6
]}

Ettrich, T. ^{[7
]}

Lindig, U. ^{[8
]}

Schulz, H. ^{[9
]}

von Weikersthal, Fischer L. ^{[10
]}

Kisro, J. ^{[11
]}

de Wit, M. ^{[12
]}

Wiebe, S. ^{[13
]}

Koenigsmann, M. ^{[14
]}

Mahlberg, R. ^{[15
]}

Fuxius, S. ^{[16
]}

Stehle, I ^{[17
]}

Kubicka, S. ^{[18
]}

Schuler, M. K. ^{[19
]}

Schnoy, E. ^{[20
]}

Ruessel, J. ^{[21
]}

Graefe, T. ^{[22
]}

Mayer, F. ^{[23
]}

Berres, M. L. ^{[24
]}

Kubin, T. ^{[25
]}

Heinemann, V ^{[26
]}

机构：

[1] Klinikum Neuperlach Klinikum Harlaching, Hamatol & Onkol, Munich, Germany

[2] MVZ Mitte, Leipzig, Germany

[3] Praxis Hamatol & Onkol, Aschaffenburg, Germany

[4] Univ Klin, Giessen, Germany

[5] Praxis Hamatol & Onkol, Landshut, Germany

[6] Ambulantes Therapiezentrum Hamatol & Onkol, Offenburg, Germany

[7] Univ Klin Innere Med, Ulm, Germany

[8] Univ Jena, Med Klin 2, Jena, Germany

[9] PIOH Praxis Internist Onkol & Hamatol, Frechen, Germany

[10] Gesundheitszentrum St Marien, Amberg, Germany

[11] Onkol Schwerpunktpraxis, Lubeck, Germany

[12] Klin Innere Med Hamatol Onkol & Palliat Med, Berlin, Germany

[13] MVZ Media Vita, Munster, Germany

[14] MediProjekt, Hannover, Germany

[15] Klinikum Borromaerinnen, Innere Med 1, Trier, Germany

[16] Tumor Ctr, Heidelberg, Germany

[17] IDGGQ, Kaiserslautern, Germany

[18] Klinikum Steinberg, Reutlingen, Germany

[19] MVZ Oskar Helene Heim, Berlin, Germany

[20] Klinikum Augsburg, Augsburg, Germany

[21] Carl von Basedow Klinikum, Merseburg, Germany

[22] Forsch Gesell Malignitat & Resultate, Hamburg, Germany

[23] Int Gemeinschaftspraxis, Friedrichshafen, Germany

[24] Univ Klin RWTH, Aachen, Germany

[25] Hamatol Onkol Klinikum Traunstein, Traunstein, Germany

[26] Med Klin III, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ep317

引用

页码：219 / 219

页数：1

共 50 条

[31] Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer
Yoshino, Takayuki
Uetake, Hiroyuki
Funato, Yuya
Yamaguchi, Yasunobu
Koyama, Takahiko
Ozawa, Daisuke
Tajiri, Masaru
Muro, Kei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 700 - 706
[32] Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.
Coutzac, Clelia
Trouilloud, Isabelle
Artru, Pascal
Henriques, Julie
Masson, Therese
De La Fouchardiere, Christelle
Doat, Solene
Bouche, Olivier
Coriat, Romain
Saint, Angelique
Moulin, Valerie
Vernerey, Dewi
Tougeron, David
Taieb, Julien
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil
Avino Tarazona, V.
Rodriguez Garces, M.
Amor Urbano, M.
Bolanos Naranjo, M.
ANNALS OF ONCOLOGY, 2021, 32 : S140 - S140
[34] Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil
Skuja, Elina
Gerina-Berzina, Aija
Hegmane, Alinta
Zvirbule, Zanete
Vecvagare, Eva
Purkalne, Gunta
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 699 - 702
[35] Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Patel, Anuj K.
Barghout, Victoria
Yenikomshian, Mihran A.
Germain, Guillaume
Jacques, Philippe
Laliberte, Francois
Duh, Mei S.
ONCOLOGIST, 2020, 25 (01): : E75 - E84
[36] Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy
Matsuoka, Serika
Fujii, Hironori
Iihara, Hirotoshi
Ohata, Koichi
Hirose, Chiemi
Watanabe, Daichi
Sadaka, Shiori
Kiyama, Shigeru
Makiyama, Akitaka
Takahashi, Takao
Kobayashi, Ryo
Matsuhashi, Nobuhisa
Suzuki, Akio
ANTICANCER RESEARCH, 2023, 43 (05) : 2351 - 2357
[37] Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia
Alghamdi, Mohammed
Bazarbashi, Shouki
Mahrous, Mervat
Alshaer, Omar
Mostafa Gad, Ahmed
Aseafan, Mohamed
Abdelgelil, Mai
Alshabi, Redhwan Mohammed
Alghanmi, Hosam Ali
Naser, Nasser Ahmed
Al Hariri, Husam
ALHamad, Abdulaziz
Al-Saleh, Khalid
Abdel-Aziz, Nashwa
Elsamany, Sherif
JOURNAL OF ONCOLOGY, 2022, 2022
[38] Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
Ozet, Ahmet
Dane, Faysal
Aykan, Nuri Faruk
Yalcin, Suayib
Evrensel, Turkkan
Ozkan, Metin
Karabulut, Bulent
Ormeci, Merve Nur
Atasev, Ozan
Vidot, Loick
Cicin, Irfan
FUTURE ONCOLOGY, 2022, 18 (29) : 3267 - 3276
[39] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
Victorino, Ana Paula Ornellas S.
Meton, Fernando
Mardegan, Luciana
Festa, Juliana
Piranda, Diogo N.
Araujo, Kelly Borges
JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
[40] Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
Patel, Anuj K.
Abhyankar, Ritika
Brais, Lauren K.
Duh, Mei Sheng
Barghout, Victoria E.
Huynh, Lynn
Yenikomshian, Mihran A.
Ng, Kimmie
Fuchs, Charles S.
ONCOLOGIST, 2021, : e2161 - e2169

← 1 2 3 4 5 →